Some justices may be skeptical of a bid by GSK, Pfizer and others to overturn ruling allowing lawsuits to proceed over claims ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

GSK is funding public health organizations working to address US adult immunization gaps and increase community vaccine education, outreach and access These grants are part of GSK’s COiMMUNITY ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of oral antibiotics for the condition in nearly 30 years. Blujepa, also ...

Shortly after President Donald Trump won his second presidential election in the U.S. last fall, British drugmaker GSK came to federal prosecutors in New York, bearing intel from employees ...

GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for ...

In spring 2021, my family sold a big lump of GSK shares. Four years later, we have no regrets. Indeed, with the GSK share price stumbling, we may buy soon. When investing, your capital is at risk.

LONDON, March 25 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles ...

GSK plans U.S. launch in second half of the year GSK expects Blujepa and other drugs to contribute to over £2 billion in peak sales Blujepa's unique action reduces bacterial resistance risk, GSK ...

Learn More. Just over a year ago, I ran the rule over GSK (LSE: GSK) shares. They looked very cheap and were offering a growing dividend. However, I chose instead to invest in FTSE 100 ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. Rise and shine, everyone, another busy day is on the way.

GSK is studying a group of more than a million older adults in the UK to see if its shingles vaccine lowers the risk of dementia. The British drugs group, led by boss Emma Walmsley, is using the ...